DE69205327D1 - Harnstoffderivate, Verfahren zu ihrer Herstellung und diese enthaltende Medikamente. - Google Patents

Harnstoffderivate, Verfahren zu ihrer Herstellung und diese enthaltende Medikamente.

Info

Publication number
DE69205327D1
DE69205327D1 DE69205327T DE69205327T DE69205327D1 DE 69205327 D1 DE69205327 D1 DE 69205327D1 DE 69205327 T DE69205327 T DE 69205327T DE 69205327 T DE69205327 T DE 69205327T DE 69205327 D1 DE69205327 D1 DE 69205327D1
Authority
DE
Germany
Prior art keywords
halogen
aryl
substituted
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69205327T
Other languages
English (en)
Other versions
DE69205327T2 (de
Inventor
Itoh Yoshikuni
Ohne Kazuhiko
Tanaka Hirokazu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919110133A external-priority patent/GB9110133D0/en
Priority claimed from GB919112823A external-priority patent/GB9112823D0/en
Priority claimed from GB919127277A external-priority patent/GB9127277D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of DE69205327D1 publication Critical patent/DE69205327D1/de
Application granted granted Critical
Publication of DE69205327T2 publication Critical patent/DE69205327T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
DE69205327T 1991-05-10 1992-05-11 Harnstoffderivate, Verfahren zu ihrer Herstellung und diese enthaltende Medikamente. Expired - Fee Related DE69205327T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919110133A GB9110133D0 (en) 1991-05-10 1991-05-10 New urea derivatives,a process for the preparation thereof and pharmaceutical composition comprising the same
GB919112823A GB9112823D0 (en) 1991-06-14 1991-06-14 New urea derivatives,a process for the preparation thereof and pharmaceutical composition comprising the same
GB919127277A GB9127277D0 (en) 1991-12-23 1991-12-23 New urea derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same

Publications (2)

Publication Number Publication Date
DE69205327D1 true DE69205327D1 (de) 1995-11-16
DE69205327T2 DE69205327T2 (de) 1996-03-28

Family

ID=27265636

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69205327T Expired - Fee Related DE69205327T2 (de) 1991-05-10 1992-05-11 Harnstoffderivate, Verfahren zu ihrer Herstellung und diese enthaltende Medikamente.

Country Status (10)

Country Link
EP (1) EP0512570B1 (de)
JP (1) JPH05140102A (de)
KR (1) KR920021523A (de)
CN (1) CN1067886A (de)
AT (1) ATE128975T1 (de)
CA (1) CA2068261A1 (de)
DE (1) DE69205327T2 (de)
IL (1) IL101785A0 (de)
MX (1) MX9202142A (de)
TW (1) TW200456B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024458A1 (en) * 1992-05-28 1993-12-09 Pfizer Inc. New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat)
TW234123B (de) * 1992-12-16 1994-11-11 Takeda Pharm Industry Co Ltd
NZ250916A (en) * 1993-02-27 1995-08-28 Nihon Nohyaku Co Ltd N-heteroaryl-n'-phenylureas, their use as acat inhibitors
US5346914A (en) * 1993-05-14 1994-09-13 Abbott Laboratories (4-alkoxypyran-4-yl) substituted arylalkylaryl-, arylalkenylaryl-, and arylalkynylarylurea inhibitors of 5-lipoxygenase
IL109568A0 (en) * 1993-05-19 1994-08-26 Fujisawa Pharmaceutical Co Urea derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
ES2076865B1 (es) * 1993-07-05 1996-08-01 Pfizer Nuevos derivados de n-aril- y n-heteroaril-urea como inhibidores de acil-coenzima a: colesterol acil transferasa (acat).
JP3720395B2 (ja) 1994-09-20 2005-11-24 京都薬品工業株式会社 新規ヘテロ環誘導体、その製造方法およびその医薬用途
PT841913E (pt) * 1995-08-04 2003-06-30 Warner Lambert Co Utilizacao de derivados sulfamico acil sulfonamidas ou sulfonil carbamatos para a producao de um medicamento para reduzir os niveis de lipoproteinas
IL123939A (en) * 1995-10-05 2001-11-25 Kyoto Pharma Ind The history of the heterocycles and the pharmaceutical preparations containing them
WO1999015520A1 (fr) * 1997-09-19 1999-04-01 Ono Pharmaceutical Co., Ltd. Composes de benzene fusionnes ou non fusionnes
EP1308438B9 (de) 2000-08-10 2012-03-28 Mitsubishi Tanabe Pharma Corporation 3-substituierte harnstoffderivate und deren medizinische verwendung
CN102050758A (zh) 2000-09-14 2011-05-11 田边三菱制药株式会社 酰胺衍生物及其制备药物的用途
MXPA03008319A (es) * 2001-03-16 2003-12-11 Abbott Lab Nuevas aminas como ligantes del receptor de histamina-3 y sus aplicaciones terapeuticas.
US6969730B2 (en) 2001-03-16 2005-11-29 Abbott Laboratories Amines as histamine-3 receptor ligands and their therapeutic applications
DK1397130T3 (da) 2001-06-20 2007-11-12 Wyeth Corp Substituerede indolsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
IL166313A0 (en) 2002-07-17 2006-01-15 Kyoto Pharma Ind Indoline derivatives and pharmaceutical compositions containing the same
AU2003296323A1 (en) 2002-12-10 2004-06-30 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
AU2003296324A1 (en) 2002-12-10 2004-06-30 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CN1723197A (zh) 2002-12-10 2006-01-18 惠氏公司 作为纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代3－烷基和3－芳基烷基1h－吲哚－1－基乙酸衍生物
DE60306548T2 (de) 2002-12-10 2007-06-21 Wyeth Substituierte 3-carbonyl-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
MX2007002178A (es) 2004-08-23 2007-04-02 Wyeth Corp Acidos de oxazolo-naftilo como moduladores del inhibidor del activador de plasminogeno tipo 1 (pai-1) util en el tratamiento de trombosis y enfermedades cardiovasculares.
WO2006023864A1 (en) 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as pai-1 inhibitors
JP2008510816A (ja) 2004-08-23 2008-04-10 ワイス チアゾロ−ナフチル酸
BRPI0606871A2 (pt) 2005-01-27 2009-07-21 Wyeth Corp "processos e compostos para a preparação de derivados de naftilindol substituìdos
AU2006279496A1 (en) 2005-08-17 2007-02-22 Wyeth Substituted indoles and use thereof
PT2239211E (pt) 2009-04-09 2014-05-07 Nestec Sa Cápsula para preparação de uma bebida com vedante de delaminação ou rompível numa parede de distribuição

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4623662A (en) * 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
IE892088L (en) * 1988-07-12 1990-01-12 William Henry Deryk Morris Quinoline derivatives, their production and use
AU632809B2 (en) * 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
AU7440691A (en) * 1990-03-12 1991-10-10 Yamanouchi Pharmaceutical Co., Ltd. Monourea derivative and its salt

Also Published As

Publication number Publication date
AU1528292A (en) 1992-11-12
ATE128975T1 (de) 1995-10-15
KR920021523A (ko) 1992-12-18
CA2068261A1 (en) 1992-11-11
IL101785A0 (en) 1992-12-30
CN1067886A (zh) 1993-01-13
JPH05140102A (ja) 1993-06-08
MX9202142A (es) 1993-06-01
AU653019B2 (en) 1994-09-15
EP0512570A1 (de) 1992-11-11
DE69205327T2 (de) 1996-03-28
TW200456B (de) 1993-02-21
EP0512570B1 (de) 1995-10-11

Similar Documents

Publication Publication Date Title
DE69205327D1 (de) Harnstoffderivate, Verfahren zu ihrer Herstellung und diese enthaltende Medikamente.
ATE206412T1 (de) Heterocyclische verbindungen als bradykinin antagonisten
DE69021472D1 (de) Pyrazolderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellung.
IL107426A0 (en) Heterocyclic compounds, processes for the preparation thereof, and pharmaceutical compositions containing the same
DE69130412T2 (de) Pyrazolopyridinverbindung und Verfahren zu ihrer Herstellung
DE69230163T2 (de) Thiazolylbenzofuranderivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
ATE60761T1 (de) Chinazolinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
NO903438D0 (no) Fremgangsmaate for fremstilling av tiazolderivater.
DE3854454D1 (de) Pyrazolopyridinverbindungen und Verfahren zu ihrer Herstellung.
DE69030206D1 (de) Pyrazolopyridinverbindungen und Verfahren zu ihrer Herstellung
MX19368A (es) Procedimiento para la preparacion de derivados heterociclicos que contienen nitrogeno benzofusionado y compuesto obtenido.
DE68926981D1 (de) Cephemverbindungen und Verfahren zu ihrer Herstellung
DE69318563T2 (de) 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONE DERIVATE, IHRE HERSTELLUNG UND DIE SIE ENTHALTENDEN ARZNEIMITTEL
DE68927554D1 (de) Cephalosporinverbindungen und Verfahren zu ihrer Herstellung
DE69024154D1 (de) Pyrimidoindolderivate und Verfahren zu ihrer Herstellung
PL304334A1 (en) Pharmaceutical composition of gastric protective action, including antiulceric one and method of treating diseases of gastrointestinal tract
HUT65376A (en) Process for preparing n,n',n-trisubstituted 5-(diamino-methylene)-1,3-dioxane-4,6-diones and pharmaceutical compositions containing them as active ingredient
DE3885978D1 (de) Cephemverbindungen und Verfahren zu ihrer Herstellung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee